Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2016 - 2025)
Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability history spans 17 years, with the latest figure at $296.0 million for Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 38.72% year-over-year to $296.0 million, compared with a TTM value of $296.0 million through Dec 2025, down 38.72%, and an annual FY2025 reading of $296.0 million, down 38.72% over the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 was $296.0 million at Teva Pharmaceutical Industries, down from $399.0 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $991.0 million in Q1 2021, with the low at $296.0 million in Q4 2025.
- Average Non-Current Deferred Tax Liability over 5 years is $591.9 million, with a median of $546.0 million recorded in 2022.
- Year-over-year, Non-Current Deferred Tax Liability tumbled 44.73% in 2022 and then increased 10.58% in 2023.
- Tracing TEVA's Non-Current Deferred Tax Liability over 5 years: stood at $784.0 million in 2021, then tumbled by 30.1% to $548.0 million in 2022, then rose by 10.58% to $606.0 million in 2023, then fell by 20.3% to $483.0 million in 2024, then plummeted by 38.72% to $296.0 million in 2025.
- Per Business Quant, the three most recent readings for TEVA's Non-Current Deferred Tax Liability are $296.0 million (Q4 2025), $399.0 million (Q3 2025), and $440.0 million (Q2 2025).